Prostate Cancer Learning Hub Supports Doctors with Online Education

Tunbridge Wells, United Kingdom, October 18, 2014 --(PR.com)-- A Prostate Cancer Learning Hub has been launched on website for healthcare professionals (HCPs), epgonline.org. The new interactive resource is designed to support medical professionals in Europe and worldwide in achieving optimum care for individual patients with the often mismanaged disease.

Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men.[1] It is thought that 30-40% of patients with prostate cancer do not currently receive optimum care, receiving either over- or under-treatment.[2]

Designed with busy doctors in mind, the online Learning Hub conveniently organises a range of education content, reference materials and decision support tools, all focusing specifically on prostate cancer. These include monthly insights from key publications, video coverage from key events, news, Continuing Medical Education programs, apps, patient materials, current treatment guidelines and clinical trials.

Free to access for urology specialists, oncologists, general practitioners and other HCPs globally at www.epgonline.org/prostate-cancer-learning-hub, the Prostate Cancer Learning Hub is hosted on epgonline.org – the website for healthcare professionals. The website is owned by UK-based company EPG Health Media (Europe) Ltd and attracts over 500,000 regular users.

"Thanks to an educational grant from Ferring Pharmaceuticals, users of epgonline.org are now able to benefit from the latest best practice guidance on tackling the burden of prostate cancer," said Chris Cooper, EPG Health Media “The new resource will be continually updated, providing valuable support for doctors who need to keep current on multidisciplinary management approaches, available treatment options and associated symptoms.”

References

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
2. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.

Notes To Editors:

Contact
Press Officer
EPG Health Media
Royal Victoria House
51-55 The Pantiles
Tunbridge Wells
Kent TN2 5TE
United Kingdom

E-Mail: www.epghealthmedia.com/contact
Web: www.epghealthmedia.com
Tel: 01892 526 776
Fax: 01892 527 669
www.twitter.com/epghealthmedia

About EPG Health Media and epgonline.org
Published by EPG Health Media (Europe) Ltd, epgonline.org is an independent website dedicated to providing healthcare professionals with free access to the most recent, best practice diagnosis and patient management guidance. In addition to the library of disease Knowledge Centres, the website includes a database of prescription drugs in 9 European languages, clinical trial reports, treatment guidelines, medical news, journal abstracts, multimedia, and apps; all arranged around 50 disease topic areas.

For further information please visit www.epghealthmedia.com and www.epgonline.org

About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in 55 countries and markets its products in more than 100 countries. To learn more about Ferring or its products please visit www.ferring.com.